Hitoshi Zembutsu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3196897/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 770-777.	4.7	244
2	Impact of <i>CYP2D6*10</i> on recurrenceâ€free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Science, 2008, 99, 995-999.	3.9	173
3	Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Science, 2019, 110, 1148-1155.	3.9	106
4	Breast cancer: The translation of big genomic data to cancer precision medicine. Cancer Science, 2018, 109, 497-506.	3.9	92
5	Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Research and Treatment, 2012, 131, 137-145.	2.5	86
6	CYP2D6 Genotyping for Functional-Gene Dosage Analysis by Allele Copy Number Detection. Clinical Chemistry, 2009, 55, 1546-1554.	3.2	75
7	Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. Scientific Reports, 2019, 9, 17358.	3.3	67
8	Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer Medicine, 2019, 8, 408-417.	2.8	63
9	Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. British Journal of Cancer, 2020, 123, 803-810.	6.4	55
10	A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Human Molecular Genetics, 2012, 21, 1665-1672.	2.9	54
11	Genomeâ€wide association study of chemotherapeutic agentâ€induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Science, 2013, 104, 1074-1082.	3.9	42
12	Significant Effect of Polymorphisms in <i>CYP2D6</i> on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. Clinical Cancer Research, 2017, 23, 2019-2026.	7.0	33
13	Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. Journal of Human Genetics, 2013, 58, 327-333.	2.3	29
14	Whole exome sequencing to identify genetic markers for trastuzumabâ€induced cardiotoxicity. Cancer Science, 2018, 109, 446-452.	3.9	25
15	Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis. PLoS ONE, 2020, 15, e0235623.	2.5	23
16	A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenetics and Genomics, 2012, 22, 229-235.	1.5	20
17	Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease. PLoS ONE, 2019, 14, e0223371.	2.5	16
18	A Genome-Wide Association Study Identifies Five Novel Genetic Markers for Trastuzumab-Induced Cardiotoxicity in Japanese Population. Biological and Pharmaceutical Bulletin, 2019, 42, 2045-2053.	1.4	14

Нітозні Zembutsu

#	Article	lF	CITATIONS
19	Pharmacogenetics for severe adverse drug reactions induced by molecularâ€ŧargeted therapy. Cancer Science, 2020, 111, 3445-3457.	3.9	13
20	Targeted sequencing reveals genetic variants associated with sensitivity of 79 human cancer xenografts to anticancer drugs. Experimental and Therapeutic Medicine, 2017, 15, 1339-1359.	1.8	3
21	A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study. PLoS ONE, 2018, 13, e0201606.	2.5	1
22	Whole-exome sequencing of 79 xenografts as a potential approach for the identification of genetic variants associated with sensitivity to cytotoxic anticancer drugs. PLoS ONE, 2020, 15, e0239614.	2.5	1
23	The association of four genetic variants with myelosuppression in gemcitabineâ€treated Japanese is not evident in gemcitabine/carboplatinâ€treated Swedes. Basic and Clinical Pharmacology and Toxicology, 2022, , .	2.5	1